Juniper Health

Juniper Biologics is a science-led healthcare company focused on the development and commercialization of innovative therapies in oncology, rare diseases, and gene therapy. Headquartered in Singapore, the company operates a robust portfolio of licensed assets, including commercial-stage products for chemotherapy-induced nausea and vomiting (CINV) and gastric cancer. Juniper is notably advancing TG-C (TissueGene-C), a first-in-class cell and gene therapy for knee osteoarthritis, through late-stage clinical development. Additionally, the company maintains strategic partnerships with organizations like Helsinn and Cartherics to expand its pipeline into novel areas such as CAR-NK cell therapies for solid tumors. Juniper Biologics aims to address significant unmet medical needs across the Asia-Pacific, Middle East, and African markets.